Financial Data and Key Metrics Changes - Total revenue for the third quarter of 2025 was $32.1 million, down 9% year-over-year and roughly flat compared to the second quarter [14] - Total bookings for the quarter were $25.4 million, down 12% year-over-year [14] - Total recurring revenue decreased by 11% compared to the prior year, with bookings driving recurring revenue down 13% for the quarter [14] - The company recorded a net loss of $4.3 million, or $0.10 per diluted share, compared to a net loss of $200,000, or $0.00 per diluted share, in the prior year [18] - Adjusted EBITDA for the third quarter was $10.3 million, with a margin of 32%, compared to $8.6 million and a margin of 24% in the prior year [19] Business Line Data and Key Metrics Changes - ClearanceJobs revenue was $13.9 million, up 1% year-over-year and up 2% sequentially, with bookings down 7% year-over-year [14] - Dice revenue was $18.2 million, down 15% year-over-year and down 1% sequentially, with bookings down 17% year-over-year [15] - ClearanceJobs had an average annual revenue per customer of $26,600, up 7% year-over-year [15] - Dice's average annual revenue per customer was $15,727, down 4% year-over-year [16] Market Data and Key Metrics Changes - The number of new tech job postings on Dice remained around 70% of normal levels, indicating a mixed macro backdrop [11] - Approximately 10% of job postings on Dice required at least one AI skill at the beginning of 2024, which has now risen above 50% [8] - The defense budget for fiscal year 2026 is proposed at $1.1 trillion, marking a 13% increase over the previous year, which is expected to benefit ClearanceJobs significantly [9] Company Strategy and Development Direction - The company focuses on providing software tools for employers and recruiters to find tech talent, with over 90% of revenue coming from subscriptions [5] - The integration of Agile ATS with ClearanceJobs aims to enhance the hiring workflow for cleared professionals [10] - The company is optimistic about future growth driven by the defense budget and increasing investments in technology initiatives across industries [23] Management's Comments on Operating Environment and Future Outlook - Management noted that tech hiring has stabilized despite remaining under historical levels, with a significant trend towards AI-related job postings [7] - The company anticipates that the record-breaking defense budget will drive growth for ClearanceJobs, while technology investments will create opportunities for both brands [23] - Management expressed confidence in the resilience of their subscription model and margin structure [13] Other Important Information - The company repurchased 741,000 shares for $2.1 million under its stock repurchase program [22] - The company is targeting total capital expenditures in 2025 to range between $7 million and $8 million, down from $13.9 million last year [21] Q&A Session Summary Question: What is driving the Dice margin expansion? - Management indicated that the margin expansion was due to headcount vacancies being backfilled and efficient cost allocation to capitalized development costs [28] Question: What was the $9 million write-off related to? - The write-off was related to the Dice trade name, which experienced revenue declines [31] Question: How is the government shutdown impacting bookings? - Management noted that smaller and mid-sized defense contractors have become more conservative, but larger firms remain bullish due to their stronger balance sheets [39] Question: What is the status of the new Dice platform migration? - Over half of the customers have migrated to the new platform, and management does not foresee churn risk with the remaining customers [41] Question: How is the company addressing customer acquisition costs with the new platform? - The introduction of a monthly subscription option has made it easier for customers to sign up, leading to an increase in new customer signings [56]

Financial Data and Key Metrics Changes - In Q3 2025, the company reported revenues of $122 million, a slight increase of approximately 1% year-on-year compared to $121 million in the prior year, and a sequential growth of 2% from Q2 [10] - Adjusted EBITDA grew by 9% year-on-year, indicating healthy margin expansion, while the company posted a net loss of $77 million primarily due to an $80 million non-cash impairment [11] - The company reaffirmed its full-year 2025 guidance, expecting broadly flat revenues compared to the prior year and an increase in adjusted EBITDA to over $85 million [9] Business Line Data and Key Metrics Changes - The company is focusing on four key areas: revamped go-to-market strategy, product innovation, operational efficiency, and audience engagement strategies [8][9] - The consolidation of intelligence and advisory brands under the Omdia banner is already yielding results in client clarity and cross-selling opportunities [11][12] - The launch of the Informa TechTarget portal has increased intent data signals by over 40% and improved performance in ROI reporting [12] Market Data and Key Metrics Changes - The B2B technology market is valued at approximately $5 trillion, with forecasts indicating it could double by 2034 [6] - The company estimates its addressable market at around $20 billion, with only 2.5% market share currently penetrated, indicating significant growth potential [7] Company Strategy and Development Direction - The company aims to leverage its scale and breadth to become an indispensable partner in the technology industry, focusing on AI, cybersecurity, and channel markets [6][8] - The strategy includes enhancing product offerings through AI-driven solutions and improving operational efficiencies to unlock cost savings [9][14] - The company is actively working on providing conversational AI interfaces to enhance customer engagement and data accessibility [15][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying strength of the combined platform and the effectiveness of strategic initiatives, noting a positive trajectory in revenue growth [10][18] - The company is optimistic about capitalizing on opportunities in the evolving technology landscape, particularly in AI and digital transformation [14][18] - Management highlighted the importance of building strong relationships with clients, which are foundational to the company's success [19] Other Important Information - The editorial teams have won 47 awards for their B2B journalism, emphasizing the value of trusted information in the market [12][13] - The company is seeing a two- to three-times higher membership conversion rate from AI-driven traffic compared to traditional search [17] Q&A Session Summary Question: What are you seeing regarding traffic driven by AI LLMs? - The company has seen increased traffic from answer engines, with a conversion rate to members two to three times higher than from traditional search [21][22] Question: How would you characterize the revenue trends year to date? - Management indicated that Q2 and Q3 revenues are back to a normalized run rate, with Q4 expected to show a 15% sequential increase due to event-based revenue from Canalys [23][24] Question: Can you comment on the pipeline for potential acquisitions? - Currently, the focus is on aligning and integrating existing assets, with serious consideration for acquisitions expected in the second half of next year [30]

Financial Data and Key Metrics Changes - For Q3 2025, total revenue was $1.1 million, a significant increase from $0.1 million in Q3 2024 [22] - Total operating costs and expenses decreased to $6.5 million from $47.8 million year-over-year, representing an 86% reduction [23] - Net loss from continuing operations was $13.1 million, compared to a net loss of $48.3 million in Q3 2024 [23] - Cash, cash equivalents, and investments as of September 30, 2025, totaled $121.1 million, extending the cash runway into 2028 [24] Business Line Data and Key Metrics Changes - The sale of FibroGen China to AstraZeneca was completed for approximately $220 million, providing access to cash and extending the company's runway [5][21] - The company is progressing with FG3246 and FG3180 in metastatic castration-resistant prostate cancer (MCRPC), with a phase two trial initiated [5][10] - Roxadustat is on track for a pivotal phase three trial for lower-risk myelodysplastic syndromes (MDS), with a regulatory path established following a successful FDA meeting [18][19] Market Data and Key Metrics Changes - The total addressable market for FG3246 in MCRPC is estimated to be over $5 billion annually [8] - Approximately 49,000 patients in the US are affected by anemia associated with lower-risk MDS, highlighting a significant market opportunity for Roxadustat [16] Company Strategy and Development Direction - The company aims to advance its mid and late-stage clinical development programs for FG3246 and Roxadustat, focusing on innovative treatment options for cancer and anemia [25] - The strategy includes leveraging the sale of FibroGen China to support US development initiatives and reduce fixed costs [24][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position to advance meaningful therapeutic options and create shareholder value [6] - The company anticipates reporting top-line results from the investigator-sponsored trial of FG3246 in combination with enzalutamide in Q1 2026 [25] Other Important Information - The company has a clear regulatory path for Roxadustat, with plans to submit the phase three trial protocol by the end of 2025 [19][25] - The company has reduced its total operating costs and expenses guidance for 2025 to between $50 million and $60 million, reflecting a 70% reduction from 2024 [24] Q&A Session Summary Question: Congratulations on closing the $220 million deal with AstraZeneca - Management acknowledged the transformative nature of the transaction [26] Question: What proportion of patients might be screened out due to thrombotic risk in the Roxadustat trial? - Management indicated that it is too early to estimate the proportion, as it depends on FDA alignment and trial data [29] Question: What is the estimated cost of the phase three trial for Roxadustat? - The estimated cost is between $50 to $60 million, assuming an enrollment of about 200 patients [29] Question: Can you provide more details on the top-line data expectations from the IST study for FG3246? - Management expects encouraging results consistent with previous efficacy estimates, particularly focusing on patient history with ARPIs [37] Question: Is the $63 million liability related to milestone payments for the ADC asset? - Management clarified that the liability is related to royalties from the royalty financing with NovaQuest Capital Management [39] Question: When will the decision be made regarding the phase three trial for Roxadustat? - Management expects to have clarity on the path forward by the second quarter of next year [44]

Financial Data and Key Metrics Changes - The company presented its annual financial report for the year ending June 30, 2025, but no specific financial data or key metrics were discussed during the meeting [5][6]. Business Line Data and Key Metrics Changes - There were no specific discussions regarding changes in data or key metrics for various business lines during the meeting [6][8]. Market Data and Key Metrics Changes - No specific market data or key metrics changes were mentioned in the meeting [6][8]. Company Strategy and Development Direction and Industry Competition - The meeting focused on formal resolutions and did not provide insights into the company's strategic direction or competitive landscape [5][6]. Management's Comments on Operating Environment and Future Outlook - Management did not provide comments on the operating environment or future outlook during the meeting [6][8]. Other Important Information - The meeting was conducted online, allowing shareholders to participate virtually and submit questions [2][3]. - Voting on resolutions was conducted by poll, with approximately 50.11% of the issued capital represented by proxies [5][6]. Q&A Session Summary Question: Any questions on the financial report? - No questions were raised regarding the financial report [7]. Question: Any questions on the management of the company? - No questions were raised regarding the management of the company [8]. Question: Any questions on the re-election of Dr. Jeremy Levin? - No questions were raised regarding the re-election of Dr. Jeremy Levin [11]. Question: Any questions on the re-election of Ms. Cathy Connell? - No questions were raised regarding the re-election of Ms. Cathy Connell [14]. Question: Any questions on the adoption of the remuneration report? - No questions were raised regarding the adoption of the remuneration report [16]. Question: Any questions on the issue of options to Lawrence Goslin? - No questions were raised regarding the issue of options to Lawrence Goslin [18]. Question: Any questions on the issue of options to Ms. Cathy Connell? - No questions were raised regarding the issue of options to Ms. Cathy Connell [20]. Question: Any questions on the issue of options to Dr. Jeremy Levin? - No questions were raised regarding the issue of options to Dr. Jeremy Levin [23].

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $163.2 million, an increase of $10.1 million or 7% from the prior year period [19] - Net income available to common shareholders was $5.6 million, nearly seven times higher than the net income of $700,000 in the prior year [20] - EPS increased significantly to $0.30 per diluted share in Q3 2025 versus $0.04 in the prior year [20] - Adjusted EBITDA increased 60% to $20.7 million compared to the prior year period, with an adjusted EBITDA margin of 13% compared to 8% in the prior year [21] Business Line Data and Key Metrics Changes - At APUS, Q3 revenue increased to $83.1 million, an 8% increase compared to the prior year, driven by an 8% increase in net course registrations [22] - Rasmussen's Q3 revenue was $60.8 million, a 16% increase fueled by a 12% increase in on-ground enrollment and an 11% increase in online enrollment [22] - Hondros College of Nursing's Q3 revenue increased 19% to $18.4 million, with total enrollment up 18% to approximately 3,700 students [23] Market Data and Key Metrics Changes - Registrations at APUS increased 8% year-over-year, while enrollments at Rasmussen increased 10% compared to Q3 2024 [8][12] - Enrollments at Hondros College of Nursing continued strong momentum, increasing 18% compared to Q3 2024 [12] Company Strategy and Development Direction - The company is focusing on growing core degree-granting businesses, particularly in military, veteran, nursing, and healthcare communities [9] - APEI is simplifying its operational structure and has submitted a new application for the combination of its institutions, expected to take effect in Q3 2026 [10][34] - The company aims to leverage existing capacity and improve financial results through enrollment growth and operational efficiencies [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the team despite government shutdown uncertainties and highlighted consistent performance over the last 18 months [16] - The company anticipates that the government shutdown will have a temporary impact on enrollments, with expectations of a return to normalcy once the situation stabilizes [32][50] - Management remains optimistic about long-term growth potential and plans to share more details at the upcoming Investor Day [30] Other Important Information - The company completed the sale of Graduate School USA, which was no longer a strategic fit, allowing a focus on core businesses [8][9] - The balance sheet improved with unrestricted cash and equivalents totaling $193.1 million as of September 30, 2025 [10][24] Q&A Session Summary Question: Plans for driving re-enrollments at APUS due to tuition assistance disruption - Management noted that several military branches are using tuition assistance funds to allow service members to register, and they have implemented marketing campaigns to re-engage dropped students [32] Question: Impact of the new process for integrating institutions on expense or revenue synergies - Management confirmed commitment to the integration and stated that the new process is procedural, with expectations for implementation in Q3 2026 [34] Question: Confirmation of a two-month slowdown for APUS registrations - Management acknowledged a slowdown in October but noted a recovery in November, with expectations for a return to normal trajectory in December [37] Question: Details on cost-saving initiatives - Management indicated that they have streamlined operations and reduced variable costs without affecting revenue-generating activities [39] Question: Trends in nursing program demand - Management reported strong growth in nursing enrollments, driven by attractive compensation and job availability in the sector [41] Question: Enrollment trends and demographic changes at Rasmussen - Management highlighted broad-based enrollment growth across campuses, with a particular focus on expanding the BSN student pool [58]

Fold Holdings (NasdaqCM:FLD) Q3 2025 Earnings Call November 10, 2025 05:00 PM ET Speaker1Good day, and thank you for standing by. Welcome to the Fold Holdings third quarter 2025 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there'll be a question-and-answer session. To ask a question during the session, you'll need to press star one-one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your questi ...

Financial Data and Key Metrics Changes - The company reported revenue of $1.5 billion for Q3 2025, representing a 20% year-over-year growth [5][16] - Adjusted EBITDA increased to $196 million, reflecting a 16% year-over-year growth, with an adjusted EBITDA margin of 13.1% [5][16] - Net income was $68 million, an increase of $52 million compared to the prior year, driven by higher operating income and reduced interest expenses [16] Business Line Data and Key Metrics Changes - Commercial aerospace revenue grew 18% year-over-year, with significant contributions from LEAP, CF-34, CFM56, and Turboprop engine platforms [6][7] - Business aviation revenue increased by 28% year-over-year, supported by growth in mid and super-mid-sized aircraft [6] - Military and helicopter revenue rose 21% year-over-year, driven by AE 1107 engine volumes and ongoing strength in C-130 transport aircraft programs [7] Market Data and Key Metrics Changes - The MRO supply-demand environment remains tight globally, with a strong backlog of MRO work [6] - The company anticipates continued favorable dynamics in the MRO market for the foreseeable future [6] Company Strategy and Development Direction - The company is focused on ramping growth platforms efficiently, driving productivity, and expanding component repair services [14] - Strategic priorities include investing in organic growth and potential acquisitions to capitalize on long-term opportunities [14] - The company is raising its 2025 guidance across all key metrics, reflecting confidence in continued operational performance [13][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's performance, which is ahead of IPO targets, and highlighted a positive market backdrop [27] - The company expects cash flow to improve significantly in Q4 due to the resolution of supply chain issues [17][63] - Management noted that the supply chain is improving, particularly regarding constrained parts, which has been a core issue throughout the year [46][63] Other Important Information - The company plans to expand its MRO facility in Winnipeg, Canada, to capture growth in the CF-34 program [11] - The company has made progress in renegotiating long-term contracts to eliminate low-margin material pass-through revenue, which is expected to improve working capital efficiency [22][23] Q&A Session Summary Question: What is the target for LEAP revenues? - Management confirmed that the target for LEAP revenues remains at a billion dollars annually in the next few years [30] Question: What are the specific parts causing supply chain choke points? - Management identified constrained parts, primarily forgings and castings, as the main issues affecting cash flow and shipment timelines [34] Question: How will the adjustments to long-term contracts impact revenue and cash flow? - Most of the revenue reduction from contract adjustments will occur in 2026, with a significant cash flow benefit expected in 2027 [38][56] Question: What is the backlog for the LEAP business? - The backlog for the LEAP business was reported to be over a billion dollars, with a 5% growth this quarter [39] Question: How is the company addressing supply chain issues? - Management indicated that they are making changes to the procurement process to ensure better access to constrained parts [63] Question: What is the outlook for business aviation? - The company is optimistic about the business aviation market, with increasing flight hours and strong demand for the HTF 7000 engine [84]

The Beachbody Company (NYSE:BODI) Q3 2025 Earnings Call November 10, 2025 05:00 PM ET Speaker5Good afternoon. Thank you for attending today's Beachbody Company third quarter 2025 earnings conference call. My name is Jayla, and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call, with an opportunity for questions and answers at the end. I'll now pass the conference over to our host, Bruce Williams, the Managing Director of ICR. You may proceed, Bruce ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $85.6 million, representing a 7% year-over-year increase and a 10% quarter-over-quarter increase, exceeding the midpoint of guidance [29] - Contribution XTAC totaled $53 million, up 12% year-over-year and 10% sequentially, reaching the high end of guidance [29] - Adjusted EBITDA for Q3 was $16 million, growing 9% year-over-year and 42% sequentially, exceeding guidance by 7% [35] Business Line Data and Key Metrics Changes - Excluding political ad spend, revenue increased 19% year-over-year, and contribution XTAC increased 22% year-over-year on a pro forma basis [30] - CTV ad spend reached a record high, accounting for 46% of total platform spend, with nearly half running through Direct Access premium publishers [32] - Contribution XTAC across the top 100 customers grew by 18% year-over-year on a trailing 12-month basis [31] Market Data and Key Metrics Changes - Spend across emerging digital channels, including CTV and streaming audio, represented approximately 56% of total platform spend in Q3, up from 50% in 2024 and 43% in 2023 [32] - The majority of leading streaming services have joined the Direct Access program, enhancing CTV ad spend [11] Company Strategy and Development Direction - The company aims to maintain its dominant position in the mid-market while expanding up-market with major U.S. advertisers and down-market to performance advertisers [21] - The launch of AI Decisioning is expected to enhance the self-service capabilities of the platform, targeting SMBs and direct-to-consumer e-commerce companies [25][44] - The partnership with Molson Coors highlights the company's ability to attract major U.S. brands seeking data-driven campaigns [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying performance, with expectations for accelerating growth in 2026 driven by new client onboarding [40] - The company anticipates easing headwinds from political ad spend starting in Q1 2026, which will positively impact revenue growth [39] - Management noted that the competitive landscape is evolving, with a focus on objectivity and independence in advertising solutions [51][53] Other Important Information - Non-GAAP net income for Q3 was $11.2 million, down 9% year-over-year, primarily due to lower interest income and higher income tax expense [35] - The company ended the quarter with $161 million in cash and cash equivalents and no debt, indicating a strong financial position [36] Q&A Session Summary Question: What is the significance of the third AI product being launched? - The third AI product, AI Decisioning, will complete the Viant AI suite, enabling full automation of ad campaigns, making it easier for advertisers to achieve their goals [44] Question: How will the merger client impact guidance? - The merger client was seasonal, and the significant impact was primarily in Q3, with minimal ongoing headwind expected [43] Question: Has competition increased from Amazon DSP? - No significant increase in competition was noted, with Amazon's DSP being a small portion of their revenue [45] Question: How will the company grow awareness among SMB advertisers? - The company plans to leverage channel partnerships and focus on demonstrating true performance to attract SMBs [46] Question: What is the expected incremental spend from the Molson Coors partnership? - While specific figures cannot be disclosed, the partnership is expected to scale significantly over the years [49] Question: How does the company view the competitive environment? - The competitive landscape is perceived as narrowing, with a focus on objectivity and serving the interests of marketers [51][53]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was $34.6 million, with subscription and other platform revenue at $32 million, and professional services revenue at $2.6 million, representing approximately 8% of total revenue [19] - Total ARR at the end of Q3 was $124.5 million, with core platform ARR at $122.4 million [20] - Gross margin in Q3 was 76%, consistent with the year-to-date gross margin of 77% [24][27] - Operating loss for Q3 was $0.4 million, or a negative 1% operating margin, compared to a loss of $0.8 million and a negative 2% margin in the same period last year [25] Business Line Data and Key Metrics Changes - The average core ARR per customer reached over $80,000 at the end of Q3, with the percentage of ARR in multi-year contracts hitting an all-time high [20][42] - The percentage of customers using two or more products also reached an all-time high, with nearly one in five customers paying for AI solutions [21][22] Market Data and Key Metrics Changes - The company experienced deal slippage in Q3, particularly in the life sciences vertical, but expects improved ARR performance in Q4 [5][20] - The $100,000 and above customer cohort represented approximately two-thirds of total ARR, with a total customer count of 1,521 at the end of Q3 [23] Company Strategy and Development Direction - The company is focused on deploying AI tools to improve efficiency and streamline operations, targeting a reduction in sales and marketing expenses as a percentage of revenue [17][31] - A new partnership with LinkedIn aims to enhance event marketing capabilities, allowing seamless integration and audience reach [8][46] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for Q4, expecting significantly better ARR performance compared to Q3, driven by improved gross retention and AI penetration [32] - The company is evaluating indications of interest for a potential acquisition, with Goldman Sachs as its financial advisor [18] Other Important Information - The company generated positive free cash flow for the seventh consecutive quarter, with Q3 free cash flow at $2.7 million [26] - The company has a strong balance sheet with approximately $175 million in cash and investments at the end of Q3 [27] Q&A Session Summary Question: Insights on AI solutions uptake - Management noted that nearly 20% of customers are paying for AI solutions, with expectations for continued growth in this area [33][34] Question: Components of go-to-market efficiency - The company has streamlined its go-to-market organization, reducing sales and marketing spending significantly while focusing on high-growth potential areas [39] Question: Deal slippage from Q3 to Q4 - Management indicated that deal slippage was primarily due to a lack of urgency in closing new business deals, with many already closed in Q4 [41] Question: Monetization opportunities from LinkedIn partnership - The partnership with LinkedIn is expected to enhance customer retention and provide monetizable opportunities through audience targeting [46][47] Question: AI search discoverability agenda - The company is focused on making content discoverable by LLMs, enhancing the indexing of webinars and derivative content [48][49]